Hilo, a Swiss healthtech company previously known as Aktiia, recently raised $19 million in a Series B extension round, with new investment from Dell Family Office. This additional funding brings Hilo's total funding to over $119 million. The company had previously closed a $42 million Series B round in May 2025.
The funding coincides with the US launch of Hilo Core, which is described as the world's first complete blood pressure health system. Hilo Core integrates a wrist-worn optical sensor, a connected FDA-cleared cuff, and a mobile application to provide continuous blood pressure insights. This system moves beyond traditional occasional cuff measurements by generating approximately 30-35 readings daily, including overnight measurements, allowing for the identification of long-term cardiovascular trends.
Stefan Petzinger, CEO of Hilo, emphasized that this approach marks a fundamental shift in blood pressure management, particularly in the US, where nearly half of adults suffer from hypertension. The aim is to empower individuals and their care teams with more comprehensive, real-world data to enable earlier and more informed actions. Hilo Core is available for $89.99 for the hardware, with an annual subscription of $149.99, making the first-year cost $239.98. It is also pre-approved for HSA and FSA eligibility.
The global blood pressure monitoring devices market was valued at $4.19 billion in 2025 and is projected to reach $8.56 billion by 2033, with a CAGR of 9.34%. Hilo's expansion into the US, along with its product development and hiring initiatives, aims to capitalize on this growing market and transition blood pressure monitoring from occasional to continuous. While the wearable band uses optical sensors, periodic cuff calibration remains essential for accuracy, with the cuff considered the gold standard for reliable measurements.
